Literature DB >> 7617825

Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity.

G R Dawson1, S P Crawford, N Collinson, S D Iversen, M D Tricklebank.   

Abstract

In exploratory animal models of anxiety, such as the elevated plus maze, the anxiogenic- and anxiolytic-like effects of drugs may be confounded by changes in locomotor activity. In the present experiments, the sensitivity of several measures of anxiety and locomotor activity in the elevated plus maze were assessed. Both chlordiazepoxide hydrochloride (CDP, 7.5 mg/kg) and d-amphetamine sulphate (AMP, 0.75, 1.5 mg/kg) increased the percent time on the open arms and doses of 7.5 mg/kg and 1.5 mg/kg CDP and AMP, respectively, increased the number of entries into the open arms. The increase in these measures might suggest that both compounds induced an anxiolytic-like effect. Although FG 7142 (30.0 mg/kg) did not decrease the number of entries to the open arms, it did decrease the time on the open arms, which might suggest that it had anxiogenic-like effects. Similarly, buspirone reduced both the number of entries into the open arms and the time spent on the open arms. However, all the compounds significantly affected locomotor activity. CDP (3.0 and 7.5 mg/kg) increased the total number of arm entries, the distance travelled on the open arms and the mean speed of the animals on the open, and in the closed arms. Moreover, the distance travelled by the animals in the closed arms was increased by 1.0 mg/kg CDP, a dose that had no measurable effects on the indices of anxiety.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617825     DOI: 10.1007/BF02245961

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery's conflict test.

Authors:  B Söderpalm; S Hjorth; J A Engel
Journal:  Pharmacol Biochem Behav       Date:  1989-01       Impact factor: 3.533

2.  A dissociation of the effects of d-amphetamine on locomotor activity and exploration in rats.

Authors:  T Robbins; S D Iversen
Journal:  Psychopharmacologia       Date:  1973-01-01

3.  Animal models for the study of anti-anxiety agents: a review.

Authors:  D Treit
Journal:  Neurosci Biobehav Rev       Date:  1985       Impact factor: 8.989

4.  The use of a plus-maze to measure anxiety in the mouse.

Authors:  R G Lister
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat.

Authors:  S Pellow; P Chopin; S E File; M Briley
Journal:  J Neurosci Methods       Date:  1985-08       Impact factor: 2.390

6.  Antianxiety properties of the angiotensin II antagonist, DUP 753, in the rat using the elevated plus-maze.

Authors:  F C Kaiser; G C Palmer; A V Wallace; R D Carr; L Fraser-Rae; C Hallam
Journal:  Neuroreport       Date:  1992-10       Impact factor: 1.837

7.  Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol.

Authors:  J C Cole; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

8.  Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG 7142 using the elevated plus-maze test in the rat.

Authors:  S Pellow; A L Johnston; S E File
Journal:  J Pharm Pharmacol       Date:  1987-11       Impact factor: 3.765

9.  Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat.

Authors:  S Pellow; S E File
Journal:  Pharmacol Biochem Behav       Date:  1986-03       Impact factor: 3.533

10.  One-trial tolerance to the effects of chlordiazepoxide on the elevated plus maze may be due to locomotor habituation, not repeated drug exposure.

Authors:  G R Dawson; S P Crawford; K J Stanhope; S D Iversen; M D Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

View more
  21 in total

Review 1.  Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models.

Authors:  Jue He; Jiming Kong; Qing-Rong Tan; Xin-Min Li
Journal:  Cell Adh Migr       Date:  2009-01-13       Impact factor: 3.405

2.  Free versus forced exposure to an elevated plus-maze: evidence for new behavioral interpretations during test and retest.

Authors:  Vincent Roy; Pierre Chapillon; Mustapha Jeljeli; Jean Caston; Catherine Belzung
Journal:  Psychopharmacology (Berl)       Date:  2008-11-08       Impact factor: 4.530

3.  Evaluation of GABAergic neuroactive steroid 3alpha-hydroxy-5alpha-pregnane-20-one as a neurobiological substrate for the anti-anxiety effect of ethanol in rats.

Authors:  Khemraj Hirani; Ajay N Sharma; Nishant S Jain; Rajesh R Ugale; Chandrabhan T Chopde
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

4.  Agonizing over antagonizing: what do benzodiazepine receptor antagonists demonstrate?

Authors:  M Sarter; G G Berntson; J P Bruno; B S Givens
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

5.  The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands.

Authors:  G Griebel; D J Sanger; G Perrault
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

6.  Localized injections of midazolam into the amygdala and hippocampus induce differential changes in anxiolytic-like motor activity in mice.

Authors:  Scott A Heldt; Kerry J Ressler
Journal:  Behav Pharmacol       Date:  2006-06       Impact factor: 2.293

7.  Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors.

Authors:  John R Atack; Peter H Hutson; Neil Collinson; George Marshall; Graham Bentley; Christopher Moyes; Susan M Cook; Ian Collins; Keith Wafford; Ruth M McKernan; Gerard R Dawson
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

8.  Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142.

Authors:  K S Sink; K N Segovia; J Sink; P A Randall; L E Collins; M Correa; E J Markus; V K Vemuri; A Makriyannis; J D Salamone
Journal:  Eur Neuropsychopharmacol       Date:  2009-12-16       Impact factor: 4.600

9.  Validation of a modified mirrored chamber sensitive to anxiolytics and anxiogenics in mice.

Authors:  Christopher L Kliethermes; Deborah A Finn; John C Crabbe
Journal:  Psychopharmacology (Berl)       Date:  2003-05-29       Impact factor: 4.530

10.  Persistent downregulation of hippocampal CREB mRNA parallels a Y-maze deficit in adolescent rats following semi-chronic amphetamine administration.

Authors:  T Featherby; M van den Buuse; D I Lubman; A J Lawrence
Journal:  Br J Pharmacol       Date:  2008-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.